Reuters logo
BRIEF-Oryzon Genomics: Roche to discontinue clinical development of ORY-1001
July 20, 2017 / 5:29 AM / 2 months ago

BRIEF-Oryzon Genomics: Roche to discontinue clinical development of ORY-1001

July 20 (Reuters) - ORYZON GENOMICS SA:

* SAYS ROCHE DECIDED TO DISCONTINUE CLINICAL DEVELOPMENT OF ORY-1001

* SAYS RIGHTS LICENSED TO ROCHE WITH RESPECT TO ORY-1001 WILL REVERT TO ORYZON WHEN TERMINATION OF LICENSE BECOMES EFFECTIVE

* SAYS WAS INFORMED THAT DECISION WAS NOT DATA DRIVEN BUT A CONSEQUENCE OF INTERNAL REPRIORITIZATION OF ROCHE’S PIPELINE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below